Harry Leider has served as a senior physician executive in a variety of innovative health care organizations. Currently, he is the chief medical officer and EVP at Gelesis, a biopharmaceutical company pioneering therapies for overweight and obesity, diabetes, and other metabolic disorders. Prior to joining Gelesis, Dr. Leider served as chief medical officer and group vice president of Walgreens and was responsible for ensuring health and wellness offerings and outcomes that provide customer value and improve patient lives. Before joining Walgreens, Leider was chief medical officer of Ameritox, a national specialty laboratory that provides adherence monitoring services for patients with chronic pain and serious mental illness. Previously, he was chief medical officer of XLHealth, a national disease management company and Medicare health plan that served seniors with chronic illnesses. In addition to his extensive background in population health, Leider has broad managed care experience. He served as the chief medical officer for HealthNet, a large hospital-owned managed care organization, and was a physician executive at Harvard Pilgrim Health Plan.

Leider is on the editorial boards of Physician Executive and the Journal of Population Health Management. He is also a founding board member of the Disease Management Association of America (DMAA) and served on the board of the Institute of Aging at the University of Pennsylvania. He also served for six years as an attending physician at Brigham and Women’s Hospital and faculty member at Harvard Medical School, and more recently as a faculty member at the Johns Hopkins Carey School of Business.

Leider earned a BA from Pennsylvania State University, an MD from the University of Pennsylvania and a MBA from the University of Washington Foster School of Business.